RESEARCH ARTICLE

Real-time assessment of corneal endothelial cell damage following graft preparation and donor insertion for DMEK

Maninder Bhogal1,2,3*, Chan N. Lwin1, Xin-Yi Seah1, Elavazhagan Murugan1, Khadijah Adnan1, Shu-Jun Lin1, Gary Peh1,4, Jodhbir S. Mehta1,2,4*

1 Singapore Eye Research Institute, Singapore, Singapore, 2 Singapore National Eye Centre, Singapore, Singapore, 3 Institute of Ophthalmology, University College London, London, United Kingdom, 4 Duke-NUS Graduate Medical School, Singapore, Singapore

* manibhogal@aol.com (M.B.); jodmehta@gmail.com (J.S.M.)

Abstract

Purpose
To establish a method for assessing graft viability, in-vivo, following corneal transplantation.

Methods
Optimization of calcein AM fluorescence and toxicity assessment was performed in cultured human corneal endothelial cells and ex-vivo corneal tissue. Descemet membrane endothelial keratoplasty grafts were incubated with calcein AM and imaged pre and post preparation, and in-situ after insertion and unfolding in a pig eye model. Global, macroscopic images of the entire graft and individual cell resolution could be attained by altering the magnification of a clinical confocal scanning laser microscope. Patterns of cell loss observed in-situ closely matched those seen on ex-vivo assessment with fluorescence viability imaging, trypan blue/alizarin red staining or scanning electron microscopy. Iatrogenic graft damage from preparation and insertion varied between 7–35% and incarceration of the graft tissue within surgical wounds was identified as a significant cause of endothelial damage.

Results
Calcein AM showed a positive dose-fluorescence relationship. A dose of 2.67μmol was sufficient to allow clear discrimination between viable and non-viable areas (sensitivity of 96.6% with a specificity of 96.1%) and was not toxic to cultured endothelial cells or ex-vivo corneal tissue. Patterns of cell loss seen in-situ closely matched those seen on ex-vivo assessment with fluorescence viability imaging, trypan blue/alizarin red staining or scanning electron microscopy. Iatrogenic graft damage from preparation and insertion varied between 7–35% and incarceration of the graft tissue within surgical wounds was identified as a significant cause of endothelial damage.

Conclusions
In-situ graft viability assessment using clinical imaging devices provides comparable information to ex-vivo methods. This method shows high sensitivity and specificity, is non-toxic and can be used to evaluate immediate cell viability in new grafting techniques in-vivo.
Introduction

Corneal disease ranks second only to cataract as the leading cause of preventable blindness[1], and corneal transplantation is the commonest tissue transplant procedure performed worldwide. Whilst scarring and infection are major causes of corneal sight-loss in the developing world, in the USA, Europe and parts of Asia (e.g. Singapore and Australia) endothelial dysfunction is the primary indication for corneal transplantation[2]. The cornea’s transparency is dependent upon the function of the non-replicative corneal endothelium, which pumps water out of the corneal stroma, maintaining corneal hydration and permitting optimal light transmission[3]. If the endothelial cell density (ECD) falls below approximately 500 cells/mm$^2$, failure of this pump layer occurs, resulting in edema, opacity and ultimately scarring and vascularization if left untreated[4]. Currently the only mechanism to replace damaged endothelial cells is transplantation.

Owing to the immunological privilege of the eye, the early success rate for penetrating keratoplasty is very high[5]. However, ongoing endothelial cell loss occurs in the transplanted tissue, and proceeds at an accelerated rate compared to that observed in the native corneal endothelium of healthy adults (4.2% for penetrating keratoplasty vs 0.3% in the native corneal endothelium) [6,7]. This means that late graft failure is a common occurrence[8] requiring re-grafting, which in itself is a common indication for keratoplasty [2]. Over the past 2 decades, endothelial keratoplasty (EK), in which the patients’ diseased endothelium is selectively replaced with donor endothelial cells, has surpassed penetrating keratolasty in developed nations[2]. However, there is concern that these more technically demanding procedures, may result in a lower number of endothelial cells being transplanted and may, therefore, have reduced survival times[9].

Pooled data from large patient series consistently show a reduction in endothelial cell density in the early post-operative period[7,10,11]. Damage to the donor cornea may occur following the initial death of the donor, harvesting of the cornea, storage of the tissue in culture media[12], graft preparation[13,14], graft insertion[15,16] and finally from manipulation within the anterior chamber.

Reducing cell loss relies upon accurate methods to assess cell viability at each stage of the transplantation process, allowing the cause at each point to be targeted for refinement. Current ex-vivo methods include staining with alizarin red S & trypan blue[17], scanning electron microscopy[16,18] and the use of fluorescence based viability dyes[19] or apoptosis assays[20], many of which are incompatible with subsequent transplantation and in-vivo assessment. An ideal assessment tool would be one in which viability can be determined at a single cell level across the entire graft[13] and performed sequentially within the same sample.

Gauthier et al performed a study comparing early post-operative cell loss following PK to whole graft viability performed in the fellow cornea from the same donor[21]. In a minimally traumatic procedure such as PK, no difference was found in early post-op cell density and that calculated after adjusting for whole graft viability. However, a significant difference between raw pre- and post-operative central cell density was found.

In EK, studies have shown graft preparation only accounts for a small percentage of the cell loss typically observed in the early post-operative period, suggesting proportionally more cells are lost from the surgical process itself[13,22]. Determination of the cell loss attributable to surgery has, until now, relied upon surgical models designed to simulate the surgery. Some of these bear poor resemblance to the surgery itself[23] and where animal models have been used, there is a need to sacrifice the animal in order to perform detailed analysis of the impact of surgery on cell survival[24]. Currently no method for immediate, detailed, in-vivo, post-operative viability assessment exists.
In this paper we present a method that allows accurate, in-situ assessment of graft viability after a single incubation of a fluorescent viability dye prior to tissue preparation. We show that changes in viability can be tracked through all stages of graft preparation and implantation using a commercially available clinical confocal scanning laser microscope. With only minor adaptation to standard setup, viability could be determined in-vivo both globally and at the single cell level.

Methods

Corneal tissue and preparation

Approval for this study was granted by the Singhealth centralized institutional review board. Experimentations were conducted in accordance with the tenets of the Declaration of Helsinki. Human corneo-scleral buttons with consent for research use were obtained from Miracles in Sight (Winson Salem, North Carolina, USA) and Lions Eye Institute for Transplant and Research (Tampa, FL, USA). Ex-vivo tissue preparation and experimentation was performed by a single surgeon (MB) with experience of >200 DMEK procedures, where transplant grade tissue with endothelial cell counts of >2200 cells/mm² and a storage time <14 days in Optisol GS (Bausch & Lomb Rochester, New York) was used. Studies involving the isolation and expansion of primary human corneal endothelial cells for in-vitro toxicity and flow cytometry studies uses research grade tissue with endothelial cell counts of >2000 cells/mm² with a similar storage time of <14 days in Optisol GS. Detailed tissue information is available in Table 1.

We have previously described our preparation method for DMEK transplants in detail[13]. In brief, manual peeling was performed on the punch block of a standard trephine (Coronet, Network Medical, UK). After 360˚ peripheral scoring with a Sinsky hook, the DM/endothelium complex was peeled 90% off, laid back flat and punched with an 8mm trephine. A triangular orientation mark was made in the periphery of the graft[25] before it was gently washed with BSS and returned to the viewing chamber for imaging.

Cell culture

Human corneal endothelial cells (HCECs) were isolated using a two-step ‘peel and digest’ method as described previously[26]. Briefly, isolated HCEC’s were first established in cornea endothelial maintenance/stabilization medium (M5-Endo) consisting of Human Endothelial-SFM supplemented with 5% Fetal Bovine Serum (FBS) (Life Technologies, Carlsbad, CA, USA) overnight. Subsequently, HCECs were cultured in a proliferative medium (M4-F99) consisting of Ham’s F12/M199, 5% FBS, 20 μg/ml ascorbic acid, 1× insulin/transferrin/sele

nium (Life Technologies) and 10 ng/ml basic fibroblast growth factor (R&D Systems, Minneapolis, MN, USA) to promote the culture of HCECs. Once HCECs became 80%–90% confluent, M5-Endo was re-introduced and cells cultured for at least two days before being passaged via trysin-EDTA dissociation. Dissociated cells were plated at a seeding density of at least 1 × 10⁶ cells/cm² in culture dishes coated with a cell attachment reagent (FNC coating mix, United States Biologicals Swampsccott, MA, USA) for subsequent cellular expansion. All cultures were incubated in a humidified atmosphere at 37˚C and 5% CO₂. Cells were collected after at least 2 rounds of passaging using the above expansion protocol and seeded at a density of 2500 cells/mm² for all in-vitro experimentation.

Fluorescence optimization

HCECs were seeded in a Greiner 96-well flat bottom polystyrol microplate (Greiner, Frickenhausein, Germany) pre-coated with FNC coating mix. Cells were incubated with varying
Table 1. Donor information.

| Serial Number | Age (Years) | Sex | Ethnicity | Time of Death to Preservation | Storage Time (Days) | Cell Count per mm² | Cause of Death | Experiments Performed |
|---------------|-------------|-----|-----------|--------------------------------|---------------------|-------------------|-----------------|----------------------|
| 1             | 44          | F   | Black     | 4H 2M                          | 11                  | 2671              | Respiratory Disease | - In-Situ Imaging  |
|               |             |     |           |                                |                     |                   |                 | - SEM               |
| 2             | 68          | M   | White     | 13H 15M                        | 12                  | 3150              | Respiratory Disease |                      |
| 3             | 63          | F   | White     | 1H 45M                         | 10                  | 3035              | Respiratory Disease |                      |
| 4             | 63          | F   | White     | 12H 16M                        | 11                  | 2903              | Respiratory Disease | - In-Situ Imaging  |
| 5             | 62          | M   | White     | 12H 44M                        | 11                  | 1681              | Heart Disease      | - Alizarin Red &    |
|               |             |     |           |                                |                     |                   |                 | - Trypan Blue Staining|
| 6             | 21          | M   | Black     | 2H 47M                         | 13                  | 3178              | Trauma            |                      |
| 7             | 58          | F   | White     | 8H 31M                         | 12                  | 2774              | Multi-Organ Failure| - In-Situ Imaging  |
| 8             | 52          | M   | White     | 6H 4M                          | 14                  | 2807              | Cancer            | - Annexin V Assay  |
| 9             | 51          | M   | White     | 20H 12M                        | 11                  | 2507              | Liver Failure      | - In-Situ Imaging  |
| 10            | 58          | M   | White     | 15H 10M                        | 11                  | 3408              | CVA               |                      |
| 11            | 46          | F   | White     | 19H 43M                        | 12                  | 2778              | Sepsis            |                      |
| 12            | 64          | M   | White     | 5H 34M                         | 12                  | 2364              | Respiratory Disease|                      |
| 13            | 65          | F   | White     | 8H 0M                          | 9                   | 2329              | Cancer            |                      |
| 14            |             |     |           |                                |                     |                   |                 |                      |
| 15            | 57          | F   | White     | 16H 55M                        | 12                  | 2477              | Heart Disease      |                      |
| 16            | 42          | M   | Black     | 14H 36M                        | 14                  | 2916              | Trauma            |                      |
| 17            | 67          | M   | Black     | 6H 51M                         | 10                  | 2824              | Sudden Cardiac Death|                      |
| 18            | 50          | M   | White     | 14H 50M                        | 14                  | 3078              | Heart Disease      | - Ex-Vivo Toxicity  |
| 19            |             |     |           |                                |                     |                   |                 | - Ex-Vivo Pan Corneal Imaging|
| 20            | 16          | M   | White     | 12H 19M                        | 11                  | 3212              | Sudden Cardiac Death|                      |
| 21            |             |     |           |                                |                     |                   |                 |                      |
| 22            | 58          | M   | Black     | 15H 52M                        | 9                   | 2003              | Heart Disease      | - Annexin V Assay  |
| 23            | 64          | M   | White     | 5H 40M                         | 12                  | 2343              | Respiratory Disease| - Ex-Vivo Pan Corneal Imaging|
| 24            | 59          | M   | White     | 6H 25M                         | 13                  | 2731              | Cancer            |                      |
| 25            | 58          | M   | Asian     | 6H 54M                         | 13                  | 3360              | End Stage Renal Disease| - In-Vitro Toxicity|
| 26            | 64          | M   | White     | 8H 9M                          | 14                  | 2801              | Heart Disease      |                      |
| 27            | 65          | F   | White     | 19H 24M                        | 11                  | 3154              | Cancer            | - Ex-Vivo Pan Corneal Imaging|
| 28            | 59          | M   | White     | 6H 16M                         | 11                  | 2335              | Renal Failure      |                      |
| 29            | 44          | F   | White     | 1H 23M                         | 12                  | 3015              | CVA               |                      |
| 30            | 58          | F   | White     | 17H 36M                        | 12                  | 2066              | Heart Disease      | - In-Vitro Toxicity  |
| 31            | 55          | M   | White     | 23H 3M                         | 12                  | 2628              | Heart Disease      |                      |
| 32            |             |     |           |                                |                     |                   |                 |                      |
| 33            | 51          | M   | White     | 6H 47M                         | 12                  | 2813              | Liver Failure      |                      |
| 34            | 24          | M   | White     | 12H 18M                        | 9                   | 3333              | Multiple Blunt Trauma|                      |
| 35            |             |     |           |                                |                     |                   |                 |                      |
| 36            | 23          | M   | White     | 18H 16M                        | 10                  | 3125              | Multi-Vehicle Accident|                      |
| 37            |             |     |           |                                |                     |                   |                 |                      |
| 38            | 21          | F   | White     | 4H 42M                         | 7                   | 3401              | Renal Failure      |                      |
| 39            |             |     |           |                                |                     |                   |                 |                      |
| 40            | 29          | F   | Black     | 21H 7M                         | 6                   | 2907              | Cholangiocarcinoma |                      |
| 41            |             |     |           |                                |                     |                   |                 |                      |
| 42            | 13          | M   | White     | 18H 59M                        | 8                   | 2865              | SI-GSW-Head        |                      |
| 43            |             |     |           |                                |                     |                   |                 |                      |
| 44            | 21          | M   | White     | 16H 41M                        | 8                   | 3205              | Bowel Obstruction  |                      |
| 45            |             |     |           |                                |                     |                   |                 |                      |

(Continued)
concentrations of calcein AM (2–8 μM) for 30 mins at 37˚C as per the manufacturer’s instructions (n = 8 per concentration). Cells were washed x3 in fresh culture media. Fluorescence intensity was measured at 540 nm using the Tecan multimode plate (Tecan infinite M200 pro, Zanker Road, San Jose, USA) reader set at an excitation frequency of 488nm. Fluorescence was measured at hourly intervals for the first 4 hours and then at varying intervals up to 96hrs. Once calcein AM concentration had been optimized in HCECs, staining was performed in whole corneas. Sequential imaging was performed in corneas stored in organ culture (37˚C) (n = 2) or Optisol (4˚C) (n = 2) for 1–14 days.

Calcein AM toxicity assessment
Toxicity assessment was conducted in HCECs and organ cultured human tissue.

Flow cytometric assessment
To determine if calcein AM had any inherent toxicity in primary cultured HCECs, a propidium iodide (PI) exclusion assay was used. Cell cultures were exposed to calcein AM (2–8μM) for 30 mins prior to washing and trypsinisation. Suspended cells were incubated in a solution containing PI in the dark for 15 minutes, following the manufacturers instructions, (BioLegend, San Diego, CA, USA), before being analyzed using a FACS Verse flow cytometer (Becton Dickinson, East Rutherford, NJ, USA) to determine the percentage of PI positive (dead) cells.

Tissue culture assessment
Two, full-thickness, 5mm discs where punched from each transplant grade cornea. One disc was incubated with calcein AM (2.67μM) for 30 minutes, washed 3 times in fresh culture media and incubated for a further 48 hrs at 37˚C. The control disc was incubated in culture media without calcein AM and washed in the same manner. After incubation, corneal discs were triple stained with calcein AM (2μM), ethidium homodimer (4μM) and Hoeschst 33323 (10μM). Samples were coated with an ophthalmic viscoelastic (Viscoat, Alcon, Forth Worth, Texas, USA) and imaged. Viability was assessed in at least 1000 cells from three non-contiguous regions free from handling/trephination damage. Percentage of dead cells, hexagonality ratio and coefficient of variation was calculated and compared between calcein AM treated cells and untreated controls.
Surgical model of DMEK

Cornea-scleral buttons were removed from the Optisol viewing chambers and placed into a 12-well culture plate. Specimens were covered with 250μl of balanced salt solution containing 2.67 μM calcein AM (1:1500 stock solution, Life Technologies Corporation) and incubated at 37˚C for 30 minutes (based on the findings of our fluorescence optimization work). Grafts were rinsed in balanced salt solution (BSS), returned to the viewing chamber and stored at room temperature until needed for imaging. Fresh porcine globes (less than 6 hours after slaughter) were obtained from a local abattoir. Experimentation was conducted either immediately after delivery (n = 10) or at 24hrs post slaughter (n = 10), allowing the cornea to swell and better simulate imaging through an edematous cornea. Globes were mounted in a customized holder and BSS was injected into the vitreous as necessary to return the ocular pressure to an approximately physiological level prior to commencing surgery. DMEK grafts that had been prepared and imaged as described earlier were peeled off fully, allowed to scroll on the stroma and stained with trypan blue dye (DORC International) for 1 minute. Excess dye was washed off and the stained DMEK scroll was transferred to a petri dish filled with BSS. The graft was drawn into a dedicated DMEK insertion device (Geuder AG, Heidelberg, Germany) and delivered into the porcine anterior chamber through a 2.8mm clear corneal incision. The grafts were unfolded using a standard ‘no touch’ technique[27] and the entire anterior chamber filled with air prior to repeat imaging of the graft in-situ. (Fig 1a)

Imaging of cell viability in-situ

Imaging was performed at three time points; prior to DMEK preparation, following DMEK preparation and in-situ imaging of unfolded DMEK graft (Fig 1b-1d). All imaging was performed using the Spectralis™ HRA confocal scanning laser ophthalmoscope (Heidelberg Engineering, Heidelberg, Germany). Calcein AM fluorescence was detected using the 488 nm solid-state excitation laser and 500 nm long-pass filter. The manufacturer-supplied anterior chamber lens was used to acquire 30–50 frames, at a fixed sensitivity of 90. These were averaged using the integrated software (Heidelberg Eye Explorer, Heidelberg Engineering) to produce a single image. To increase image magnification, and allow visualization of individual cells, a x40 air interface microscope objective lens (Nikon, Tokyo, Japan) or the Rostock module(Heidelberg), a simple lens system containing a x63 water immersion lens, were coupled to the supplied 30˚ retinal lens using customized collars.

Image analysis

All images were exported to Image J (National Institute for Health, Bethesda, USA) for processing and quantification. Mean fluorescence was measured from multiple 25x25 pixel arrays (Fig 2a). Signal-to-noise ratio was defined as the mean fluorescence intensity for the entire array divided by the standard deviation of fluorescence intensity (derived by measuring the intensity of each pixel within the array). Fluorescence contrast was calculated by dividing mean fluorescence of viable areas by that of adjacent non-viable areas. The periphery of the graft was chosen as a standardized area of non-viable tissue as this region is known to contain both dead cells and patches of bare Descemet membrane (Fig 2b).

To determine if calcein AM staining alone was sufficient to allow automated cell density determination, cell counting was performed on images acquired with the x40 lens array using the ITCN plugin for ImageJ. Cell density measurements generated from in-situ images were compared to those generated from the same region of the cornea by counting Hoechst positive nuclei (see later).
In-vitro viability

Immediately after the in-situ imaging, corneas in the porcine model were excised and the DMEK grafts carefully harvested. Comparisons between our in-situ imaging method and widely used, ex-vivo methods of graft viability assessment were made.

Fluorescent viability assessment

Calcein AM/ethidium homodimer staining is frequently used in cell biology applications to detect live/dead cells respectively. Grafts were incubated in BSS containing Calcein am (2μM) ethidium homodimer (4μM) and Hoechst 33323 (10μM) for 30 mins. Grafts were transferred to a customized curved viewing chamber and fluorescence imaged with a x4 objective lens on the Nikon TLE inverted fluorescence (Nikon) using our previously described method[13]. This allowed imaging of the entire graft, meaning a comparison between our in-situ and in-vitro
methods could be conducted in the same regions of the transplant. A Bland-Altman analysis was conducted to determine if measurement of cell density derived from in-situ calcein AM fluorescence showed good agreement with that derived using nuclear counter staining with Hoechst.

**Trypan blue/Alizarin red S staining**

Trypan blue/Alizarin red S viability staining is frequently used in ex-vivo graft assessment [16]. Cell borders are stained by alizarin red and dead cell nuclei stain with trypan blue. Both dyes stain and bare Descemet membrane (on both the stromal and endothelial surfaces),
which can be problematic when assessing DMEK tissue as the stromal surface of the DM is exposed. The corneas were stained with 0.4% Trypan blue (Sigma-Aldrich Corp., Singapore) for 1 minute and rinsed with phosphate buffered saline (PBS, 0.01 M, Life Technologies, Carlsbad, CA, USA). The corneas were subsequently stained with 0.5% Alizarin red S (Sigma-Aldrich Corp.) for 2 minutes, and rinsed again with PBS prior to imaging on an upright light microscope with a 3-colour CCD.

**Scanning electron microscopy**

Samples were fixed in glutaraldehyde 2% immediately after sacrifice. Corneas were washed twice in PBS for 10 minutes each before being immersed in 1% aqueous solution of osmium tetroxide (FMB, Singapore) for 2 hours at room temperature. Samples were then dehydrated using increasing concentrations of ethanol (25%, 50%, 75%, 95% to 100% ethanol, with 95% and 100% concentrations being performed twice) prior to critical point dried using Bal-Tec dryer (Balzers, Liechtenstein) and mounting on stubs secured by carbon adhesive tape. They were then sputter coated with a 10-nm-thick layer of gold (Bal-Tec) and examined using the JSM-5600 scanning electron microscope (JEOL, Tokyo, Japan).

**Annexin V staining**

To determine if calcein AM fluorescence could detect endothelial cells undergoing early apoptosis, 2 transplants were incubated in calcein AM blue (Excitation 322nm/Emission 435nm) and Annexin V conjugated to FITC from an apoptosis detection kit following the manufacturer’s instructions (BioLegend), San Diego, CA, USA) and imaged on the fluorescence microscope.

**Statistical analysis**

Statistical analysis was conducted using GraphPad Prism 7.0 (GraphPad Software Inc, La Jolla, CA, USA). A p-value of <0.05 was deemed to be significance in all tests. Comparison between 2 groups of variables was performed using two-sided t-tests or the Wilcoxon rank test if the data was non-parametric. Where appropriate, paired sample analysis was performed. When comparing groups of three or more, analysis was performed using ANOVA.

**Results**

**Optimization of calcein AM for in-vivo imaging**

A linear dose:fluorescence relationship was observed for calcein AM staining in cultured endothelial cells (Fig 3a). Of the 4 concentrations tested, 2.67 μM was found to be the minimal concentration sufficient for imaging with the Spectralis™ HRA. This was the lowest concentration at which discrimination between viable and dead cells, both globally and at an individual cell level, could be performed reproducibly. In the majority of samples stained with 2.67μM calcein AM, nuclear staining was greater than that of the cytoplasm, thereby aiding semi-automated cell counting. As calcein AM concentration increased, the contrast between nuclear and cytoplasmic fluorescence reduced.

After incubation and washing in fresh media, fluorescence continued to peak for a further two hours (Fig 3b.), after which time point it began to rapidly decline (Fig 3c). Fluorescence was also assessed in whole corneas stored in different culture media (n = 4). By 24 hours, fluorescence dropped considerably and contrast was insufficient to discriminate between viable and non-viable regions in grafts stored in organ culture at 37˚C. There was little change in mean fluorescence or contrast for grafts stored in Optisol GS at 4˚C for up to 2 weeks (Fig 3d).
Effect of CAM on in-vitro and ex-vivo cell viability

Uptake of PI for HCECs exposed to different concentrations of calcein AM was compared to that of unstained cells using flow cytometry. There was a correlation between calcein AM concentration and PI uptake, however, cell viability was not significantly different between unstained cells and those treated with 2.67 μM calcein AM (2.72% vs 3.96%, p = 0.25, ANOVA) (Fig 4f). For ex-vivo corneas, the ECD, hexagonality ratio and the percentage of dead cells was not significantly between control and treatment corneas incubated with 2.67 μM calcein AM (Fig 4a–4e).

In-situ global imaging of graft viability using a porcine model

The porcine model replicated the steps of DMEK accurately and showed good face validity. Use of the anterior segment module supplied with Spectalis™ HRA allowed imaging of the
entire graft at three time points (prior to graft preparation, following DMEK graft preparation and in-situ imaging post graft insertion). High quality images were obtained when imaging through either fresh or 24hr-old, swollen porcine corneas.

Fluorescent contrast between viable and non-viable areas was 15.41 (95% CI 8.78–22.0) with an average signal-to-noise ratio of 14.27 (95% CI 11.87–16.66). A receiver-operator-characteristic was plotted using mean fluorescence intensity from 50 viable and non-viable graft areas. Setting a fluorescent intensity of 40 units as a cut-off for thresholding viable areas achieved a sensitivity of 96.6% with a specificity of 96.1% (Fig 2c).

Degree of iatrogenic damage attributable to graft insertion and unfolding in DMEK

Iatrogenic damage varied between 7–35% of the total graft area. Scenarios encountered clinically, such as tissue being incarcerated inside the main incision/paracentesis during insertion (n = 3) (Fig 5a), tissue being ejected from the eye (n = 1) (Fig 5b) and use of torn tissue (n = 2) (Fig 5c), were experienced in the pig eye surgical model. Whilst only seen in a small number of cases, each of these events was associated with a distinctive patterns of cell loss. Incarceration of tissue during insertion or unfolding resulted in loss of cells in that region. Multiple linear areas of cell loss were seen on the tissue ejected from the eye. Both of these patterns are
consistent with physical trauma to the endothelial cells that lie on the outside of the tissue scroll. In two cases in which torn tissue was inserted, there was no significant cell loss in the areas adjacent to the tear or the flap.

**Comparison between in-situ and conventional in-vitro viability assessment methods**

Areas of non-viability detected using the in-situ imaging showed good agreement with our global, in-vitro viability method (grafts had been re-incubated with Calcein AM and Ethidium Homodimer to confirm the loss of fluorescence accurately represented iatrogenic cell damage) (Fig 6a–6c).

Higher magnification imaging allowed visualization of individual cells (Fig 6d and 6e). Estimates of cell density based on calcein AM fluorescence showed a strong, positive correlation with counting Hoechst positive cells from the same graft region ex-vivo (R = 0.74, p<0.0001). There was a bias when counting cells based on in-situ calcein AM fluorescence; with this method detecting on average 187 fewer cells per mm$^2$ (95%CI 120–250 cells/mm$^2$) (Fig 6f).

In addition, we compared in-vivo viability imaging to three other viability assessment methods: trypan blue/alizarin red staining, scanning electron microscopy and annexin V fluorescence. All methods showed the same patterns of cell loss; areas of bare Descemet membrane surrounded by attached but non-viable cells (trypan blue or ethidium homodimer positive) (Fig 7). In-situ, these non-viable cells could easily be seen at higher magnifications, in particular with use of the Rostock module (Fig 7a). Attached, dead cells had significantly diminished fluorescence (only marginally higher than that of the bare DM) allowing for easy discrimination between non-viable and viable attached cells.

Triple staining with calcein AM blue (live cells), ethidium homodimer (late apoptotic and necrotic cell death) and FITC conjugated annexin V (detects early apoptosis) showed no overlap between calcein AM and either of the dead cell stains, indicating that endothelial cells in both early and late stages of cell death are calcein AM negative (Fig 7).
In this study we describe a method for in-situ endothelial viability assessment using a single, short incubation with a fluorescent viability dye and a widely available clinical imaging device. To our knowledge, this is the first time a method for global in-situ graft viability assessment following corneal transplantation has been described. The method shows a very high sensitivity and specificity allowing easy segmentation of viable and non-viable areas of the graft at both the global and individual cell level. This detailed level of information is comparable to more time consuming in-vitro methods that required the tissue to be disposed of following staining eg. alizarin red/trypan blue dual staining or scanning electron microscopy. In-situ

**Discussion**

In this study we describe a method for in-situ endothelial viability assessment using a single, short incubation with a fluorescent viability dye and a widely available clinical imaging device. To our knowledge, this is the first time a method for global in-situ graft viability assessment following corneal transplantation has been described. The method shows a very high sensitivity and specificity allowing easy segmentation of viable and non-viable areas of the graft at both the global and individual cell level. This detailed level of information is comparable to more time consuming in-vitro methods that required the tissue to be disposed of following staining eg. alizarin red/trypan blue dual staining or scanning electron microscopy. In-situ
Calcein AM imaging does not miss cells in the early stages of apoptotic cell death, suggesting it may have an advantage over other non-toxic viability dyes\cite{28}.

In current clinical practice, endothelial cell density is measured using specular or bright field microscopy of tissue prior to transplantation and specular or confocal microscopy in patients following transplantation. These measurements are prone to sampling errors, as cell density is not uniform across the cornea, increasing from the corneal apex to its periphery\cite{29}, and localized cell density can vary by as much as 10% within the central cornea alone\cite{30}.

Additionally, there is an assumption that all cells seen are viable. Inferences about the viability of the entire graft, made from cell density measurements taken from small, central areas of confluent cells, can be inaccurate\cite{19} and falsely elevate the cell loss attributed to surgery itself\cite{21}.

Calcein AM requires two conditions in order to positively label cells. Firstly, the cells must be metabolically active for their cytoplasmic esterases to cleave calcein AM into fluorescent calcein. Secondly, in order for the polar calcein molecule to be retained within the cytoplasm, the cell membrane must remain intact. Iatrogenic damage occurring during the grafting process results in endothelial cell membrane compromise\cite{18}. Our findings suggest this is sufficient to allow rapid escape of calcein through new cell membrane perforations, resulting in a loss of fluorescence and allowing new areas of non-viable cells to be identified at multiple time-points after the initial incubation, without the need for re-staining.

---

**Fig 7. High magnification in-vivo, electron-microscopy and immuno-fluorescence live/dead imaging.** (A) High magnification in-vivo images were taken using the Rostock corneal module. Individual cells and cell nuclei are clearly visible. Dead cells still attached to Descemet membrane (DM) (red arrow head) and bare areas of DM (green arrow can be seen). Scale bar 50\(\mu\)m. (B) The same patterns of cell loss (i.e. bare DM surrounded by dead cells) can be seen on trypan blue/alizarin red (Scale bar 50\(\mu\)m) viability staining and (C) scanning electron microscopy (100\(\mu\)m). (D) DMEK grafts triple stained with calcein AM blue, annexin V and ethidium show no overlap between calcein AM and early or late markers of apoptosis. Scale bar 100\(\mu\)m.

https://doi.org/10.1371/journal.pone.0184824.g007
Whilst descriptions of cell loss during DSAEK insertion have been evaluated and used to modify insertion methods[16,31,32], to our knowledge, no descriptions of the patterns of cell loss occurring during DMEK tissue unfolding have been reported. Our findings suggest events a surgeon may associate with significant cell loss, such as unfolding torn tissue, may not significantly impact graft viability, and may not be automatic indications to discard tissue. Conversely, brief incarceration of tissue within a paracentesis, a not infrequent occurrence for those learning DMEK, resulted in significant cell damage in our limited study. Owing to the small samples size, further evaluation of the impact of specific surgical maneuvers is necessary to draw definitive conclusions.

The porcine eye model has been used to assess the feasibility of transplanting tissue engineered corneal grafts[33] and has long been used as a training model for corneal transplantation including DMEK[34]. The model has good face validity. Adding in-situ viability assessment to this model provides a good surrogate for animal surgery and will allow new modalities of EK and insertion devices to be assessed in a more realistic manner prior to clinical use.

Our method allows single cell viability can be determined in-vivo by the addition of contact or non-contact objective lenses to the confocal laser ophthalmoscope. At present this cannot be performed across the entire graft but approximates of global viability can be generated by combining information about macroscopic areas of cell death/loss with density and viability information taken from multiple high power fields[19], thereby partly compensating for the known variations in cell density across the graft.

In most samples, brighter nuclear staining with calcein AM was observed allowing these maxima to be used for semi-automate cell density assessment. This method seemed to systematically under-estimated cell density, with a bias of approximately 200 cells/mm$^2$. However, all measurements fell between the 95% limits of agreement and therefore, with appropriate calibration, this method should give an accurate estimate of regional cell density. We noticed some pincushion distortion caused by the customized in-vivo optical set-up and this would account for lower cell density measurements. It should be possible to correct this with appropriate adaption of the imaging system.

We did not observe significant toxic effects for calcein AM used at a dose of 2.67μM in-vitro or ex-vivo and have begun use of calcein AM staining as part of our quality control process in animal models of EK. Grafts have cleared successfully without any observed differences between labeled and unlabeled controls, indicating calcein AM staining is not toxic in-vivo (data not shown). As work on tissue engineered grafts and cell injection therapy continues, a method of in-vivo viability assessment and cell imaging will be valuable[35]. Immediate in-vivo viability imaging will allow researchers to determine if graft failure is a consequence of iatrogenic cell loss during surgery or deficiencies in the cells being transplanted.

Whilst calcein AM has an excellent ability to determine graft viability, the fact it remains unbound within the cytoplasm means it is released from cells relatively quickly and is, therefore, not suitable as a long-term tracker. This seems to be an active process as corneas stored at 4˚C retain fluorescence for at least 14 days, whereas it is rapidly lost in those stored in ex-vivo culture at 37˚C. Our in-vivo experience reflects this, with fluorescence from calcein AM not visible 24hrs after transplantation. However, the most important time point at which to determine viability is immediately after surgery, meaning loss of fluorescence does not detract from the use of calcein AM for this indication. Use of other covalently linked dyes may allow longer-term tracking but these would likely stain dead but attached cells giving false positive results.

Fluorescent imaging is widely adopted in ophthalmology, with the Spectralis™ HRA designed primarily for clinical fluorescein angiography. Recently the combination of this
clinical device and fluorescent apoptosis markers has been proposed as a clinical tool to detect glaucoma and Parkinson’s disease[36,37]. Whilst it would be straightforward to use calcein AM staining clinically, its use is currently restricted. To our knowledge, there is no good manufacturing process grade calcein AM available. Should this become available it is conceivable that a single incubation of graft tissue with calcein AM would be sufficient to allow assessment of graft viability at every stage from harvesting to implantation. Further work looking at long term tracking of endothelial cells in-vivo, such as the use of quantum dots [38] or fluorescent probes [39], is warranted, with the possibility of multiplexing these with calcein AM.

In summary, we have established a method for sequential graft viability assessment that can be used at every stage of transplantation. The methodology utilizes currently available clinical imaging devices and with minor modifications allows global (whole graft) and cell level viability and density assessment in-vivo.

Author Contributions
Conceptualization: Maninder Bhogal, Jodhbir S. Mehta.
Data curation: Maninder Bhogal, Chan N. Lwin.
Formal analysis: Maninder Bhogal, Gary Peh.
Funding acquisition: Jodhbir S. Mehta.
Investigation: Maninder Bhogal, Chan N. Lwin, Xin-Yi Seah, Elavazhagan Murugan, Khadijah Adnan, Shu-Jun Lin, Gary Peh.
Methodology: Maninder Bhogal.
Project administration: Maninder Bhogal.
Resources: Maninder Bhogal, Gary Peh, Jodhbir S. Mehta.
Supervision: Maninder Bhogal, Gary Peh, Jodhbir S. Mehta.
Visualization: Maninder Bhogal.
Writing – original draft: Maninder Bhogal.
Writing – review & editing: Maninder Bhogal, Gary Peh, Jodhbir S. Mehta.

References
1. Tan DTH, Dart JKG, Holland EJ, Kinoshita S. Corneal transplantation. Lancet. Elsevier; 2012; 379: 1749–1761. https://doi.org/10.1016/S0140-6736(12)60437-1
2. 2015 Eye Banking Statistical Report, Eye Bank Association of America [Internet].
3. Meek KM, Knupp C. Corneal structure and transparency. Prog Retin Eye Res. 2015; 49: 1–16. https://doi.org/10.1016/j.preteyeres.2015.07.001 PMID: 26145225
4. Bourne WM, Kaufman HE. The endothelium of clear corneal transplants. Arch Ophthalmol. 1976; 94: 1730–1732. PMID: 788691
5. George AJT, Larkin DFP. Corneal transplantation: the forgotten graft. Am J Transplant. Munksgaard International Publishers; 2004; 4: 678–685. https://doi.org/10.1111/j.1600-6143.2004.00417.x PMID: 15084160
6. Møller-Pedersen T. A comparative study of human corneal keratocyte and endothelial cell density during aging. Cornea. 1997; 16: 333–338. PMID: 9143808
7. Bourne WM, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. Invest Ophthalmol Vis Sci. 1997; 38: 779–782. PMID: 9071233
8. Bourne WM. Cellular changes in transplanted human corneas. Cornea. 2001. pp. 560–569. PMID: 11473153
9. Coster DJ, Lowe MT, Keane MC, Williams KA, Australian Corneal Graft Registry Contributors. A comparison of lamellar and penetrating keratoplasty outcomes: a registry study. Ophthalmology. Elsevier; 2014; 121: 979–987. https://doi.org/10.1016/j.ophtha.2013.12.017 PMID: 24491643

10. Price MO, PJ MD FW. Endothelial cell loss after descemet stripping with endothelial keratoplasty influencing factors and 2-year trend. Ophthalmology. Elsevier; 2008; 115: 857–865. https://doi.org/10.1016/j.ophtha.2007.06.033 PMID: 17688873

11. Dirisamer M, Ham L, Dapena I, Moutsouris K, Droutsas K, van Dijk K, et al. Efficacy of descemet membrane endothelial keratoplasty: clinical outcome of 200 consecutive cases after a learning curve of 25 cases. Arch Ophthalmol. 2011; 129: 1435–1443. https://doi.org/10.1001/archophthalmol.2011.195 PMID: 21746971

12. Doughman DJ. Prolonged donor cornea preservation in organ culture: long-term clinical evaluation. Trans Am Ophthalmol Soc. 1980; 78: 567–628. PMID: 7020215

13. Bhogal M, Balda MS, Matter K, Allan BD. Global cell-by-cell evaluation of endothelial viability after two methods of graft preparation in Descemet membrane endothelial keratoplasty. Br J Ophthalmol. BMJ Publishing Group Ltd; 2016; 56: bjophthalmol–2015–307534.

14. Terry MA, Saad HA, Shamie N, Shah N. Peripher al endothelial cell damage after trephination of donor tissue. Cornea. 2009; 28: 1149–1152. https://doi.org/10.1097/ICO.0b013e3181a87a28 PMID: 19770708

15. Saad HA, Terry MA, Shamie N, Chen ES, Friend DF, Holiman JD, et al. An easy and inexpensive method for quantitative analysis of endothelial damage by using vital dye staining and Adobe Photoshop software. Cornea. 2008; 27: 818–824. https://doi.org/10.1097/ICO.0b013e3181705ca2 PMID: 18650669

16. Mehta JS, Por YM, Poh R, Beuerman RW, Tan D. Comparison of donor insertion techniques for descemet stripping automated endothelial keratoplasty. Arch Ophthalmol. 2008; 126: 1383–1388. https://doi.org/10.1001/archophht.126.10.1383 PMID: 18852416

17. Ide T, Yoo SH, Kymionis GD, Goldman JM, Perez VL, O’Brien TP. Descemet-stripping automated endothelial keratoplasty: effect of anterior lamellar corneal tissue-on/off storage condition on Descemet-stripped automated endothelial keratoplasty donor tissue. Cornea. 2008; 27: 754–757. https://doi.org/10.1097/ICO.0b013e31816a6266 PMID: 18650658

18. Madden PW. The evaluation of endothelial damage following corneal storage: a comparison of staining methods and the value of scanning electron microscopy. Curr Eye Res. 1987; 6: 1441–1451. PMID: 2448064

19. Pipparelli A, Thuoret G, Toubeau D, He Z, Piselli S, Lefèvre S, et al. Pan-corneal endothelial viability assessment: application to endothelial grafts preselected by eye banks. Invest Ophthalmol Vis Sci. Association for Research in Vision and Ophthalmology; 2011; 52: 6018–6025. https://doi.org/10.1167/iovs.10-6641 PMID: 21662243

20. Albon J, Tullo AB, Aktar S, Boulton ME. Apoptosis in the endothelium of human corneas for transplantation. Invest Ophthalmol Vis Sci. 2000; 41: 2887–2893. PMID: 10967041

21. Gauthier A-S, Garcin T, Thuret G, He Z, Jullienne R, Trone M-C, et al. Very early endothelial cell loss after penetrating keratoplasty with organ-cultured corneas. Br J Ophthalmol. BMJ Publishing Group Ltd; 2016; bjophthalmol–2016–309615. https://doi.org/10.1136/bjophthalmol-2016-309615 PMID: 27965261

22. Rose L, Bricé OA, Stark WJ, Gloria DG, Jun AS. Assessment of eye bank-prepared posterior lamellar corneal tissue for endothelial keratoplasty. Ophthalmology. Elsevier; 2008; 115: 279–286. https://doi.org/10.1016/j.ophtha.2007.04.020 PMID: 17599413

23. Kendo N, Okumura N, Kinoshita S. Development of new therapeutic modalities for corneal endothelial disease focused on the proliferation of corneal endothelial cells using animal models. Exp Eye Res. 2012; 95: 60–67. https://doi.org/10.1016/j.exer.2011.10.014 PMID: 22067130

24. Bhogal M, Maurino V, Allan BD. Use of a single peripheral triangular mark to ensure correct graft orientation in Descemet membrane endothelial keratoplasty. J Cataract Refract Surg. Elsevier; 2015; 41: 2022–2024.

25. Peh GSL, Toh K-P, Wu F-Y, Tan DT, Mehta JS. Cultivation of human corneal endothelial cells isolated from paired donor corneas. PLoS ONE. Public Library of Science; 2011; 6: e28310. https://doi.org/10.1371/journal.pone.0028310 PMID: 22194824
27. Dapena I, Moutsouri S, Droutsas K, Ham L, van Dijk K, Melles GRJ. Standardized “no-touch” technique for descemet membrane endothelial keratoplasty. Arch Ophthalmol. American Medical Association; 2011; 129: 88–94. https://doi.org/10.1001/archophthalmol.2010.334 PMID: 21220634

28. Gain P, Thuret G, Chiquet C, Dumollard JM, Mosnier JF, Burillon C, et al. Value of two mortality assessment techniques for organ cultured corneal endothelium: trypan blue versus TUNEL technique. British Journal of Ophthalmology. 2002; 86: 306–310. PMID: 11864889

29. Amann J, Holley GP, Lee S-B, Edelhauser HF. Increased endothelial cell density in the paracentral and peripheral regions of the human cornea. Am J Ophthalmol. 2003; 135: 584–590. https://doi.org/10.1016/S0002-9394(02)02237-7 PMID: 12719063

30. Schimmelpfennig BH. Direct and indirect determination of nonuniform cell density distribution in human corneal endothelium. Invest Ophthalmol Vis Sci. 1984; 25: 223–229. PMID: 6365828

31. Terry MA, Saad HA, Shamie N, Chen ES, Phillips PM, Friend DJ, et al. Endothelial keratoplasty: the influence of insertion techniques and incision size on donor endothelial survival. Cornea. 2009; 28: 24–31. https://doi.org/10.1097/ICO.0b013e318182a4d3 PMID: 19092400

32. Kuo AN, Harvey TM, Afshari NA. Novel delivery method to reduce endothelial injury in descemet stripping automated endothelial keratoplasty. Am J Ophthalmol. 2008; 145: 91–96. https://doi.org/10.1016/j.ajo.2007.08.036 PMID: 17996209

33. Levis HJ, Peh GSL, Toh K-P, Poh R, Shortt AJ, Drake RAL, et al. Plastic compressed collagen as a novel carrier for expanded human corneal endothelial cells for transplantation. Mohan RR, editor. PLoS ONE. Public Library of Science; 2012; 7: e50993. https://doi.org/10.1371/journal.pone.0050993 PMID: 23226443

34. Droutsas K, Petrak M, Melles GRJ, Koutsandrea C, Georgalas I, Sekundo W. A simple ex vivo model for teaching Descemet membrane endothelial keratoplasty. Acta Ophthalmol. 2014; 92: e362–5. https://doi.org/10.1111/aos.12371 PMID: 24725378

35. Fuest M, Yam GH-F, Peh GSL, Mehta JS. Advances in corneal cell therapy. Regen Med. Future Medicine Ltd London, UK; 2016; 11: 601–615. https://doi.org/10.2217/rme-2016-0054 PMID: 27498943

36. Normando EM, Davis BM, De Groef L, Nizari S, Turner LA, Ravindran N, et al. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson’s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta Neuropathol Commun. BioMed Central; 2016; 4: 86. https://doi.org/10.1186/s40478-016-0346-z PMID: 27535749

37. Cordeiro MF, Guo L, Luong V, Harding G, Wang W, Jones HE, et al. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci USA. National Acad Science; 2004; 101: 13352–13356. https://doi.org/10.1073/pnas.0405479101 PMID: 15340151

38. Genicio N, Gallo Paramo J, Shortt AJ. Quantum dot labeling and tracking of cultured limbal epithelial cell transplants in vitro. Invest Ophthalmol Vis Sci. The Association for Research in Vision and Ophthalmology; 2015; 56: 3051–3059. https://doi.org/10.1167/iovs.14-15973 PMID: 26024089

39. Hsiung P-L, Hsiung P-L, Hardy J, Friedland S, Soetikno R, Du CB, et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med. 2008; 14: 454–458. https://doi.org/10.1038/nm1692 PMID: 18345013